Recently, the international journal Nature Communications published the latest research results of MTS-105, an innovative drug independently developed by Yitai Technology, in the field of liver cancer treatment. MTS-105 produces bispecific antibodies through mRNA encoding, which can act as a linker. Studies have shown that the mRNA encoded bispecific antibody T cell linker achieves complete clearance of tumor cells and induces long-term T cell immune memory in a mouse model of hepatocellular carcinoma, and is expected to become the world's first mRNA encoded T cell linker (TCE) solid tumor therapy. It is reported that immunotherapy based on TCE has been widely clinically validated in hematological tumors. However, its application in solid tumors faces many obstacles, including insufficient T cell infiltration, immunosuppressive tumor microenvironment, and systemic toxicity risks. The MTS-105 developed by the team adopts a "Trojan horse" strategy, abandoning traditional therapies of systemic attack. By accurately targeting GPC3 lipid nanoparticles in liver cells, TCE is generated and released on a large scale inside and around solid tumors, effectively activating T cells to kill tumor cells, significantly improving local efficacy and optimizing pharmacokinetic properties. In mouse, rat, and crab eating monkey models, MTS-105 exhibits high tissue specificity and excellent safety compared to traditional therapies, significantly reducing the risk of systemic toxicity. In a mouse model, at a dose as low as 0.15 micrograms of the drug, the experimental mice achieved complete tumor clearance, and the cured mice maintained a tumor free state even after being vaccinated with new tumors, demonstrating long-term immune memory effects and effectively preventing tumor recurrence. The paper shows that with the help of the AI driven nano delivery platform developed by Yitai Technology, the team designed an efficient delivery system and achieved the best balance in mRNA sequence design, significantly improving the translation efficiency and stability of mRNA. Previously, the team published research results on an innovative mRNA therapeutic vaccine in the Journal of Cancer Immunotherapy. This study also used precise targeted delivery technology to deliver vaccines to the spleen, significantly improving antigen presentation efficiency. At the same time, the dual subtype and multi-target intelligent and safe antigen design significantly enhances the anti-tumor efficacy and more effectively activates HPV specific CD8+(a type of cell surface protein) T cells. Xu Wei, the corresponding author of the paper and Chief Scientific Officer of Zhitai Technology, stated that the therapeutic application of mRNA based nucleic acid drugs has always faced bottlenecks, and the key breakthrough lies in the innovation of mRNA delivery carriers. By using targeted delivery systems to deliver drugs into dense solid tumors, the effectiveness of treatment will be greatly improved. At present, MTS-105 has obtained orphan drug qualification certification from the US Food and Drug Administration. (New Society)